The annual meeting of the American Society of Clinical Oncology is the most visible showcase for new cancer drug data. Join industry leaders, scientific experts, and STAT reporters for an ...

Gilead Sciences’ bid to extend the uses of TROP2-directed Trodelvy into lung cancer currently rests on the results of its EVOKE-01 study, revealed for the first time at this year’s ASCO.

Novartis looks odds on to extend the indications of its CDK4/6 inhibitor Kisqali into early-stage breast cancer, on the back of data from the phase 3 NATALEE trial reported at the ASCO congress.

The Journal of Clinical Oncology podcast, hosted by Dr. Shannon Westin and Dr. Davide Soldato, presents analyses and discussions centered on the latest findings published in ASCO’s esteemed Journal of ...

CME Provider: Med Learning Group is offering a series of virtual events during the 2025 ASCO Annual Meeting. These events are organized and accredited by Med Learning Group and supported by ...